The Safety and Effectiveness of Zidovudine Plus Adefovir in HIV-Infected Patients
Phase 1
Completed
- Conditions
- HIV Infections
- Registration Number
- NCT00002326
- Lead Sponsor
- Gilead Sciences
- Brief Summary
To study the safety, tolerance, pharmacokinetics, and anti-HIV effects of combination zidovudine (AZT) and PMEA (adefovir) therapy.
- Detailed Description
Patients receive AZT daily and intravenous PMEA three times weekly for 4 weeks. An MTD will be defined for this regimen.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the anti-HIV effects of zidovudine and adefovir combination therapy?
How does the zidovudine-adefovir regimen compare to standard nucleoside reverse transcriptase inhibitor combinations in HIV treatment?
Which biomarkers correlate with improved virological response to zidovudine plus adefovir in HIV-infected patients?
What are the most common adverse events associated with combination zidovudine and adefovir treatment in clinical trials?
How do other nucleotide analogs like tenofovir compare to adefovir in combination with zidovudine for HIV therapy?
Trial Locations
- Locations (1)
Natl Cancer Institute
🇺🇸Bethesda, Maryland, United States
Natl Cancer Institute🇺🇸Bethesda, Maryland, United States